{
    "clinical_study": {
        "@rank": "80579", 
        "arm_group": [
            {
                "arm_group_label": "Sitagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Sitagliptin 0.1 daily for 1 year"
            }, 
            {
                "arm_group_label": "acarbose", 
                "arm_group_type": "Active Comparator", 
                "description": "acarbose 150mg daily for 1 year"
            }
        ], 
        "brief_summary": {
            "textblock": "Cardiovascular complications account for the highest mortality in type 2 diabetic patients,\n      mainly due to coronary artery disease (CAD).Left ventricular hypertrophy (LVH) is widespread\n      in type 2 diabetic patients with CAD, even in the absence of hypertension .It is a strong\n      predictor of cardiovascular events and all-cause mortality .\n\n      Sitagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP-4), may regress left ventricular\n      mass (LVM) in type 2 diabetic patients with CAD ."
        }, 
        "brief_title": "Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Coronary Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Patients had to have the levels of hemoglobin A1c (HbA1c) > 7.0 %. They\n        also had to have either angiographically documented coronary artery disease or a previous\n        history of myocardial infarction. In addition, they were also required to have an office\n        BP < 135/85 mm Hg and the presence of LVH on echocardiography (American Society of\n        Echocardiography criteria LVM index [LVMI] > 115 g/m2 for men and > 95 g/m2 for women) .\n        -\n\n        Exclusion Criteria:Patients were excluded if they were currently prescribed GLP-1\n        analogues or DPP-4 inhibitors or glucosidase inhibitor, had a previous adverse reaction to\n        DPP-4 inhibitors or glucosidase inhibitor. They were also excluded if they had renal and\n        liver dysfunction, heart failure, or malignancy, or were unable to give informed consent.\n        Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers,\n        claustrophobia) were also excluded, as were pregnant or lactating women.  -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863147", 
            "org_study_id": "2010Wze052"
        }, 
        "intervention": {
            "arm_group_label": [
                "Sitagliptin", 
                "acarbose"
            ], 
            "description": "Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.", 
            "intervention_name": "Sitagliptin and acarbose", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Acarbose", 
                "Sitagliptin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Type 2 diabetes", 
            "left ventricular mass", 
            "inhibitor of dipeptidyl peptidase-4"
        ], 
        "lastchanged_date": "August 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430070"
                    }, 
                    "name": "Guangda Xiang"
                }, 
                "status": "Completed"
            }, 
            {
                "contact": {
                    "last_name": "Xiang Guangda, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430070"
                    }, 
                    "name": "Wuhan General Hospital"
                }, 
                "investigator": {
                    "last_name": "Xiang Guangda, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease", 
        "overall_contact": {
            "email": "Guangda64@hotmail.com", 
            "last_name": "Xiang Guangda, MD,PhD", 
            "phone": "2768878410", 
            "phone_ext": "+86"
        }, 
        "overall_official": {
            "affiliation": "Wuhan General Hospital of Guangzhou Command", 
            "last_name": "Xiang Guangda, MD,PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cardiac magnetic resonance (CMR) imaging was performed at baseline and at 12 months for left ventricular mass and left ventricular volume.", 
            "measure": "Left ventricular mass and left ventricular volume", 
            "safety_issue": "Yes", 
            "time_frame": "2013~2014(follow up 1 year)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863147"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wuhan General Hospital of Guangzhou Military Command", 
            "investigator_full_name": "Xiang Guang-da", 
            "investigator_title": "director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Endothelial function was assessed on three visits (baseline, month 6, and month 12) by measuring flow-mediated dilation (FMD) of the brachial artery in response to hyperemia according to our previous reports.\nPulse wave analysis and pulse wave velocity (PWV) were measured at baseline, 6 months visit, and 12 months visit.", 
            "measure": "Endothelial function and augmentation index (AIx)", 
            "safety_issue": "Yes", 
            "time_frame": "2013~2014 (follow up 1 year)"
        }, 
        "source": "Wuhan General Hospital of Guangzhou Military Command", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wuhan General Hospital of Guangzhou Military Command", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2011"
    }
}